Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer
19218
post-template-default,single,single-post,postid-19218,single-format-standard,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-5.7,vc_responsive

Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer

发表时间：2014-06-17 13:27

编辑于 13:27h 学术成果, 研究论文

 

a b s t r a c t

Pancreatic cancer is a devastating disease with a dismal prognosis. Surgical resection is the only curative option but is heavily hampered by delayed diagnosis. Due to few therapeutic treatments available, novel and efficacious therapy is urgently needed. Histone deacetylase inhibitors (HDACIs) are emerging as a prominent class of therapeutic agents for pancreatic cancer and have exhibited significant anticancer potential with negligible toxicity in preclinical studies. Clinical evaluations of HDACIs are currently underway. HDACIs as monotherapy in solid tumors have proven less effective than hematological malig- nancies, the combination of HDACIs with other anticancer agents have been assessed for advanced pan- creatic cancer. In this review, we describe the molecular mechanism underpin the anticancer effect of HDACIs in pancreatic cancer and summarize the recent advances in the rationales of combination strat- egies incorporating HDACIs. In addition, we discuss the importance of identifying predictors of response to HDACI-based therapy.

第一署名医院：南京鼓楼医院

Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer （查看pdf）